ARTICLE | Preclinical News
Apelin is a potential sarcopenia therapeutic
July 30, 2018 9:41 PM UTC
A paper in Nature Medicine suggests that apelin (APLN) could help treat sarcopenia as well as serve as a biomarker of the age-related disease characterized by skeletal muscle loss.
Researchers from University of Toulouse and colleagues first observed that plasma APLN levels were reduced in a cohort of elderly patients with age-related loss of muscle in the Phase III MAPT trial. In a mouse model of aging, plasma APLN levels and skeletal muscle APLN and APLN receptor (APLNR; APJ) mRNA expression decreased with age...
BCIQ Company Profiles